BioXcel Therapeutics enters ATM equity distribution agreement for up to $8.135M

BioXcel Therapeutics, Inc.

Entered Equity Distribution Agreement with Canaccord Genuity LLC on April 3, 2025.
May sell up to $8,135,000 of common stock via at-the-market offerings under existing shelf registration.
Canaccord receives up to 3.0% commission on gross proceeds; Company reimburses certain expenses.
Shares sold through Nasdaq or other trading market at prevailing prices with no minimum price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.